Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
Related to this article
In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The liquid biopsy identifies ESR1 mutations in blood to select patients with metastatic breast cancer who may be eligible for treatment with camizestrant.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
TRE-515 earned fast track status in combination with KRAS inhibitors for G12C-mutated NSCLC after anti–PD-(L)1 therapy and platinum-based chemotherapy.
An NDA for zipalertinib in EGFR exon 20 insertion–positive NSCLC is being supported by phase 3 REZILIENT3 data.
Advertisement
Advertisement
Trending on OncLive
1
VIR-5500 Receives FDA Fast Track Designation in mCRPC
2
Targeted Approaches in Pancreatic Cancer, Chemo Intensification in CRC Take Center Stage as Key GI Oncology Presentations at ESMO 2026
3
Next-Generation NAMPT Inhibitors Aim to Revive a Stalled Target in AML and MDS
4
Guardant360 CDx Receives European Approval as Companion Diagnostic for Camizestrant in ESR1-Mutated Advanced Breast Cancer
5